國家衛生研究院 NHRI:Item 3990099045/5549
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 852406      Online Users : 1596
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/5549


    Title: Induction chemotherapy with gemcitabine, oxaliplatin, and 5-Fluorouracil/Leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study
    Authors: Ch'ang, HJ;Lin, YL;Wang, HP;Chiu, YF;Chang, MC;Hsu, CH;Tien, YW;Chen, JS;Hsieh, RK;Lin, PW;Shan, YS;Cheng, AL;Chang, JY;Whang-Peng, J;Hwang, TL;Chen, LT
    Contributors: National Institute of Cancer Research;Division of Biostatistics and Bioinformatics
    Abstract: PURPOSE: To evaluate the therapeutic efficacy of 3-month triplet induction chemotherapy (ICT) followed by concomitant chemoradiotherapy (CCRT) in patients with locally advanced pancreatic cancer (LAPC). PATIENTS AND METHODS: Chemonaive patients with measurable, histologically confirmed LAPC were eligible. The ICT consisted of biweekly gemcitabine (800 mg/m(2)) infusion at a fixed dose rate (10 mg/m(2)/min), followed by 85 mg/m(2) oxaliplatin and 48-h infusion of 5-fluorouracil/leucovorin (3000/150 mg/m(2)) for 6 cycles. Patients without disease progression 4 weeks after ICT would receive weekly 400 mg/m(2) gemcitabine and 5040 cGy radiation in 28 fractions. After CCRT, patients were subjected for surgical intervention and/or maintenance chemotherapy until progression or intolerable toxicity. RESULTS: Between December 2004 and August 2008, 50 patients were enrolled. The best responses after ICT were partial response (PR) in 9, stable disease in 26, and progressive disease or not evaluable in 15. Among the former 35 patients, 2 had disease progression before CCRT, and 3 declined to have CCRT. Of the 30 patients receiving CCRT, an additional 4 and 1 patient(s) achieved PR at the end of CCRT and during maintenance chemotherapy, respectively. On intent-to-treat analysis, the overall best response was PR in 14 patients and stable disease in 21. The overall response rate and disease control rate were 28% (95% confidence interval [CI], 16.2-42.5%) and 70% (95% CI, 44.4-99.2%), respectively. The median time to progression and overall survival of the intent-to-treat population was 9.3 (95% CI, 5.8-12.8) months and 14.5 (95% CI, 11.9-17.1) months, respectively. One- and two-year survival rates were 68% (95% CI, 55.1-80.9%) and 20.6% (95% CI, 8.7-32.5%), respectively. Neutropenia was the most common Grade 3-4 toxicity of both ICT and CCRT, with a frequency of 28% and 26.7%, respectively. Significant sensory neuropathy occurred in 9 patients (18%). CONCLUSION: Three months of triplet ICT followed by gemcitabine-based CCRT is feasible, moderately active, and associated with encouraging survival in patients with LAPC.
    Date: 2011-12
    Relation: International Journal of Radiation Oncology, Biology, Physics. 2011 Dec;81(5):e749-e757.
    Link to: http://dx.doi.org/10.1016/j.ijrobp.2010.10.034
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0360-3016&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000306334300010
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=81855166622
    Appears in Collections:[Li-Tzong Chen] Periodical Articles
    [Jang-Yang Chang] Periodical Articles
    [Jacqueline Whang-Peng(1996-2007)] Periodical Articles
    [Hui-Ju Mandy Ch'ang] Periodical Articles
    [Yen-Feng Chiu] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB21420250.pdf160KbAdobe PDF833View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback